Beijing Geekgene Technology Co.LTD
TCR-T cells(Beijing Geekgene Technology Co., LTD)은 Colorectal Cancer 표적 세포·유전자 치료로, Gastric Cancer; Esophageal Cancer 영역에서 개발·상용화 중입니다. 작용기전: bispecific molecule and αPRAME 425 TCR T-cells each exhibited potent, T-cell mediated cytotoxicity against PRAME + NUT carcinoma cells. 전임상 단계입니다. 대표 임상 효능: ORR 50% (ClinicalTrials.gov NCT05943990). 차별점: novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β.
Colorectal Cancer
Gastric Cancer; Esophageal Cancer
Recruiting
NK cell recognition via the "missing-self" response
retrovirally transduced to express KRAS G12D-targeting TCRs, and expanded for 10 days in t
humanized patient-derived xenograft model of Claudin18
novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β
bispecific molecule and αPRAME 425 TCR T-cells each exhibited potent, T-cell mediated cytotoxicity against PRAME + NUT carcinoma cells
T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation
biomarker to enrich tumor-reactive CD8⁺ TILs and to improve adoptive cell transfer strategies in futur
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Beijing Geekgene Technology Co.LTD
TCR-T cells(Beijing Geekgene Technology Co., LTD)은 Colorectal Cancer 표적 세포·유전자 치료로, Gastric Cancer; Esophageal Cancer 영역에서 개발·상용화 중입니다. 작용기전: bispecific molecule and αPRAME 425 TCR T-cells each exhibited potent, T-cell mediated cytotoxicity against PRAME + NUT carcinoma cells. 전임상 단계입니다. 대표 임상 효능: ORR 50% (ClinicalTrials.gov NCT05943990). 차별점: novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β.
Colorectal Cancer
Gastric Cancer; Esophageal Cancer
Recruiting
NK cell recognition via the "missing-self" response
retrovirally transduced to express KRAS G12D-targeting TCRs, and expanded for 10 days in t
humanized patient-derived xenograft model of Claudin18
novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β
bispecific molecule and αPRAME 425 TCR T-cells each exhibited potent, T-cell mediated cytotoxicity against PRAME + NUT carcinoma cells
T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation
biomarker to enrich tumor-reactive CD8⁺ TILs and to improve adoptive cell transfer strategies in futur
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.